
    
      The study aim is to evaluate the toxicity and activity of a therapeutic approach to high
      doses with support of peripheral blood stem cells (PBSC) in patients aged ≥ 65 and ≤75 years,
      chemosensitive relapsed or refractory to therapy first line in terms of event free survival
      (EFS) and treatment related mortality (TRM)
    
  